Pomdoctor Limited is terminating its ADR program and moving to a direct listing of Class A ordinary shares on the Nasdaq, streamlining its capital structure for investors.
Pomdoctor Limited is transitioning its listing structure by terminating its American Depositary Receipt (ADR) program. The company will shift to trading its Class A ordinary shares directly on the Nasdaq, a strategic move to streamline its capital structure and simplify its equity presence for investors.
Pomdoctor Limited has commenced the termination of its American Depositary Receipt program.
The company will transition to trading its Class A ordinary shares directly on the Nasdaq exchange.
Pomdoctor Limited announced the termination of its American Depositary Receipt (ADR) program effective immediately. The digital healthcare firm will transition its primary trading to Class A ordinary shares on the Nasdaq exchange, marking a structural shift in its equity listing strategy.
The company is terminating the ADR program, which typically involves the conversion of ADRs into the underlying Class A ordinary shares for investors.
The company's Class A ordinary shares will continue to trade on the Nasdaq exchange.